Rejuvenation Technologies Inc.
mRNA therapeutics to extend healthspan entering clinical trials
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months. Rejuvenation Technologies Inc. is a Y Combinator company (Summer 2018). YC-listed status: Active.
- Website
- rejuvenationtech.com
- Location
- San Francisco, CA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Rejuvenation Technologies — mRNA-based telomere extension therapy using proprietary lipid nanoparticle delivery to reverse cellular aging in specific tissues. · Other
Links
- Y Combinator profileycombinator